Play

More cancers were diagnosed in 2023 than in the previous year, the American Cancer Society says, but cancer deaths are not rising at the same rate. William Nelson, director of the Kimmel Cancer Center at Johns Hopkins, says as our …

Reducing cancer rates will rely on a more complete understanding of what causes the disease, Elizabeth Tracey reports Read more »

Play

While overall cancer deaths are continuing their decline, there are three that are still problematic, the most recent data from the American Cancer Society demonstrates. Johns Hopkins Kimmel Cancer Center director William Nelson names them. Nelson: The ones to watch …

Deaths from certain cancers continue to rise, Elizabeth Tracey reports Read more »

Play

The annual analysis of the American Cancer Society reports that while the overall number of new cancers diagnosed is higher than last year, deaths from cancers are not rising along with the new cases. Sidney Kimmel Cancer center director William …

The American Cancer Society reports many new cancers but not rising deaths, Elizabeth Tracey reports Read more »

Play

Sleep difficulties or insomnia are common, and the problem is growing. The latest data reveals that about a third of us have the condition, with women affected more often than men. Psychiatrist Andrew Huhn at Johns Hopkins says to address …

Can your sleep patterns be making you sick? Elizabeth Tracey reports Read more »

Play

Something called the blood brain barrier prevents many things, including most drugs, from entering your brain. Now a new study that disrupts the barrier using ultrasound seems to have shown that antibodies to treat Alzheimer’s disease can gain entry this …

Can a novel way to get antibodies into the brain help Alzheimer’s disease? Elizabeth Tracey reports Read more »

Play

Monoclonal antibodies for Alzheimer’s disease, like the drug called Aduhelm, attach to aberrant proteins thought to be one cause of the disease, but they only stand to benefit a small number of the people who might be at risk. That’s …

Only a small percentage of people are candidates for monoclonal antibodies to treat Alzheimer’s disease, Elizabeth Tracey reports Read more »

Play

Aduhelm is a type of drug called a monoclonal antibody, and it’s used to remove some of the aberrant proteins thought to cause Alzheimer’s disease. Lolita Nidadavolu, a geriatrics expert at Johns Hopkins, says there is much to consider when …

Who is a candidate for monoclonal antibodies for Alzheimer’s disease? Elizabeth Tracey reports Read more »